Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Stopped early · Not applicable
Conditions studied: Hereditary Clear Cell Renal Cell Carcinoma, Kidney Cancer
In brief
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with locally advanced or metastatic kidney cancer.
Key facts
- Study ID
- NCT00727532
- Run by
- Northwestern University
- People needed
- 9
- Starts
- 2008-07-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2019-05-03
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.